Type 2 Diabetes Mellitus Clinical Trial
Official title:
A Randomised Trial of the Cost Effectiveness of Screening and Intensive Multi-factorial Intervention for Type 2 Diabetes
Diabetes is a common chronic condition associated with the risk of heart disease, and eye
and kidney damage. Many people are diagnosed with diabetes when they develop symptoms or
complications, suggesting that the true onset of disease occurs years earlier. Early
detection of diabetes may result in health benefits, but this is not proven. People of South
Asian origin are at more risk of having diabetes and of getting the heart disease
complications associated with it. The study aims to test whether screening for diabetes is
feasible in a South Asian population and to measure the benefits of early detection and
intensive treatment.
Hypothesis: A program of screening and an intensive multi-factorial intervention for type 2
diabetes is both feasible and cost effective within primary care.
Although diabetes is commonly undiagnosed and many patients have evidence of complications
at diagnosis, there is no definitive evidence that early detection improves health outcomes.
One of the critical but uncertain factors is the extent to which screening and subsequent
treatment reduces cardiovascular risk. Multi-factorial cardiovascular risk reduction in
people with prevalent diabetes and microalbuminuria results in a halving of heart disease
risk. However, it is not certain whether this result can be generalised to patients without
microalbuminuria or those whose disease is screen-detected.
The ADDITION study is a collaborative randomised controlled trial of a target-driven
intensive multi-factorial approach to cardiovascular risk reduction in patients with
screen-detected type 2 diabetes mellitus, aimed at assessing the feasibility of screening in
a primary care setting and quantifying the cardiovascular benefits and economic and
psychological costs of screening. The study as a whole will have the power to determine
whether screening and the intensive multi-factorial intervention results in improved
cardiovascular outcomes. The ADDITON-Leicester study will contribute to this collaboration,
but which by itself will demonstrate the feasibility of screening and measure the effect of
the ADDITION study intervention on modelled cardiovascular risk at 1 year after detection by
screening in a population at high risk by virtue of having a high proportion of people from
South Asia (Leicester). The study is also assessing the impact of intensive intervention of
modelled cardiovascular risk at 1 year.
People of South Asian origin are at increased risk of having diabetes and of developing
heart disease. The issues of screening are thus particularly relevant to this population.
However, all of the populations currently recruited to ADDITION are predominantly Caucasian.
The ADDITION-Leicester study will assess the feasibility of systematic screening in a South
Asian population, will quantify the effect of intensive treatment in people with screen
detected diabetes on modelled cardiovascular risk at 1 year and will assess the economic and
psychological costs of screening and intensive treatment. This study population will then
contribute to the ADDITION-Europe study, which as a whole is powered to assess the impact of
screening and intensive treatment on 5 year cardiovascular outcomes.
;
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT02252224 -
Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance
|